Protagonist Therapeutics director Daniel Swisher resigns from board; board shrinks to six
Director Daniel N. Swisher Jr., a member of the Audit Committee, resigned from Protagonist Therapeutics' board effective September 17, 2024, and will continue as an advisor under an advisory agreement. The filing says he did not report any disagreement with the company, and the board was reduced from seven seats to six, with Sarah A. O'Dowd added to the Audit Committee effective September 19, 2024.
Key points
- Daniel N. Swisher Jr. resigned from the Board effective September 17, 2024, and was an Audit Committee member
- Swisher will continue to serve as an advisor under an advisory agreement
- Sarah A. O'Dowd was appointed to the Audit Committee effective September 19, 2024
- Board size reduced from seven to six members
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 20, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.